Abstract

The Biostatistics and Bioinformatics Core B will centralize biostatistics and bioinformatics services and will provide support in genomic data processing, analysis, interpretation, and compute infrastructure, as well as experimental design of laboratory experiments and validation studies, as needed by the Projects and other Cores to achieve their Specific Aims. The Research Projects in this PO1 require a broad range of statistical and bioinformatics expertise and the Core provides a team of dedicated personnel to support genomic profiling studies, including mutation detection and allele-specific copy number analysis from DNA sequencing data, RNA-Sequencing data processing and analysis, maintenance of high-performance computing storage, and design of pre-clinical and validation studies.

Public Health Relevance

The overall goal of the Biostatistics and Bioinformatics Core B is to ensure streamline services in genomic data processing, analysis, storage, and design of laboratory experiments and validations, and to assist the PO1 investigators in their achievement of their overall research objective: developing new targets for therapy for carcinomas of the lung.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA129243-11
Application #
9417597
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-13
Budget End
2019-08-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Yu, Helena A; Planchard, David; Lovly, Christine M (2018) Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book :726-739
Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel et al. (2018) Differential Effector Engagement by Oncogenic KRAS. Cell Rep 22:1889-1902
Ruscetti, Marcus; Leibold, Josef; Bott, Matthew J et al. (2018) NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362:1416-1422
Du, Zhenfang; Lovly, Christine M (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:58
Yu, Helena A; Suzawa, Ken; Jordan, Emmet et al. (2018) Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clin Cancer Res 24:3108-3118
Westover, D; Zugazagoitia, J; Cho, B C et al. (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29:i10-i19
Li, Bob T; Shen, Ronglai; Buonocore, Darren et al. (2018) Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol 36:2532-2537
Fan, Pang-Dian; Narzisi, Giuseppe; Jayaprakash, Anitha D et al. (2018) YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A 115:E6030-E6038
Mo, Qianxing; Shen, Ronglai; Guo, Cui et al. (2018) A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics 19:71-86
Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736

Showing the most recent 10 out of 188 publications